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Abstract
Background—Older adults are often exposed to multiple medications, some of which could be 
inappropriate or have the potential to interact with each other. Older cancer patients may be at 
increased risk for medication-related problems due to exposure to cancer-directed treatment.
Methods—We described patterns of potentially inappropriate medication (PIM) use and potential 
drug-chemotherapy interactions among adults age 66+ years diagnosed with stage I–III breast, 
stage II–III colon, and stage I–II lung cancer. Within the Surveillance, Epidemiology, and End 
Results-Medicare database, patients had to have Medicare Part D coverage with 1+ prescription in 
the diagnosis month and Medicare Parts A/B coverage in the prior 12 months. We estimated 
monthly prevalence of any and cancer-related PIM from 6 months pre- to 23 months post-cancer 
diagnosis and 12-month period prevalence of potential drug-chemotherapy interactions.
Results—Overall, 19,318 breast, 7,283 colon, and 7,237 lung cancer patients were evaluated. 
Monthly PIM prevalence was stable pre-diagnosis (37–40%), but increased in the year following a 
colon or lung cancer diagnosis, and decreased following a breast cancer diagnosis. Changes in 
PIM prevalence were driven primarily by cancer-related PIM in patients on chemotherapy. 
Potential drug-chemotherapy interactions were observed in all cohorts, with prevalent interactions 
involving hydrochlorothiazide, warfarin, and proton-pump inhibitors.
Conclusions—There was a high burden of potential medication-related problems among older 
cancer patients; future research to evaluate outcomes of these exposures are warranted.
Impact—Older adults diagnosed with cancer have unique medication management needs. Thus, 
pharmacy specialists should be integrated into multidisciplinary teams caring for these patients.
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Introduction
As the prevalence of multiple chronic conditions increases with age, older adults (age 65+ 
years) and their healthcare providers often must manage the use of multiple prescription 
medications. At the same time, age-related changes in body composition and organ function 
can alter the way the body processes and reacts to drugs, making older adults more sensitive 
to both the intended and unintended effects of medications.(1) A recent study reported that 
nearly 40% of older Americans were taking 5 or more prescription drugs (i.e., 
polypharmacy) in the prior 30 days.(2) This is concerning given that polypharmacy is 
associated with an increased risk of drug-drug interactions and adverse drug events (ADEs).
(3) In addition, polypharmacy increases the chances that an older adult will be prescribed a 
potentially inappropriate medication (PIM) – i.e., a drug that has a high risk of an ADE 
relative to its potential benefit, when safer, more effective and well tolerated options are 
available.(4, 5) Taken together, exposure to polypharmacy, drug-drug interactions, and PIM 
have serious consequences for the healthcare system, increasing the use of avoidable 
healthcare services and costs, but also for older adults, decreasing functional capacity and 
quality of life.(6–10)
As the proportion of cancer patients diagnosed at age 65 years and older is expected to reach 
70% by 2030,(11) medication management among this population is a growing public health 
concern.(12) Compounding the medication management complexities relevant to all older 
adults is the fact that older adults with cancer are also exposed to cancer-directed treatments, 
including chemotherapy, which have the potential to interact with concomitant medications 
used to manage other acute and chronic conditions.(13) Furthermore, cancer patients also 
frequently use supportive care medications, some of which are considered PIMs, to manage 
cancer symptoms (e.g., pain and insomnia) and treatment-related side effects (e.g., nausea 
and diarrhea). As such, individualized assessment and scrutiny of these medications and 
their benefit-risk balance, considering life expectancy, cancer aggressiveness, and other co-
existing conditions, is necessary to optimize medication use in this unique patient 
population.
At the population-level, documentation of the prevalence of cancer-related PIM use and 
drug-drug interactions could help alert oncology providers to these problems and highlight 
subgroups of patients who have high exposure and for whom targeted intervention and 
medication reviews may be warranted. To generate such knowledge, we conducted a large, 
population-based study of older adults newly diagnosed with breast (I–III), colon (stage II–
III), and lung (stage I–II) cancer to: (1) describe the monthly prevalence of PIM use from 6 
months before through 23 months following cancer diagnosis, with a specific emphasis on 
cancer-related PIM and (2) quantify the 12-month period prevalence of potential drug 
interactions among patients treated with specific chemotherapeutic agents.
Materials and Methods
Data source and study population
We drew upon the Surveillance, Epidemiology and End Results program (SEER)-Medicare 
database,(14) a linkage of cancer registry and Medicare enrollment and claims data. This 
Lund et al. Page 2
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2019 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
linked database includes cancer cases through 2011 and Medicare claims through 2013. 
Medicare Part A and B claims provide information on diagnoses and procedures in the 
hospital and outpatient setting and Part D claims provide information on prescription drug 
dispensing (available from 2007–2012).
For this study, we identified adults aged 66 years and older who were diagnosed with a first, 
primary cancer of the colon (American Joint Commission on Cancer 6th Edition (AJCC) 
stage II or III), breast (AJCC stage I–III), or lung (AJCC stage I–II) from 2007–2011. These 
cancer sites and stages were selected to identify populations that might receive 
chemotherapy, excluding older adults diagnosed with advanced stage disease, where the 
risk-benefit assessment of PIM use is less clear. To be included in the study cohort, 
individuals had to have: (1) at least 12 months of continuous Medicare enrollment in Parts A 
and B prior to their diagnosis date (set to the first day of the month of diagnosis) to assess 
relevant comorbid conditions, (2) Medicare Part D (prescription drug) coverage during the 
month of diagnosis, and (3) at least one prescription medication dispensed in the month of 
diagnosis. Individuals who were diagnosed at autopsy, did not survive throughout the month 
of diagnosis, or had a missing month of diagnosis were excluded.
Patient demographic, clinical, and cancer treatment characteristics
Demographic and tumor characteristics were obtained in the month of diagnosis, including 
age, sex, race (White, Black, Other), marital status (married, single, divorced/widowed/ 
separated), year of diagnosis, and AJCC stage. Using Medicare claims data, we assessed 
comorbidity using the Charlson Comorbidity Index(15) (categorized as 0, 1, 2+) during the 
12-months prior to the month of diagnosis and medication burden using a count of the 
number of unique prescriptions (generic name level) in the month prior to the month of 
diagnosis (categorized as 0–2, 3–5, 6–9, 10+). Using the same 12-month period, we 
estimated each individual’s predicted probability of being frail based on an internally(16) 
and externally(17) validated Medicare claims-based model including 20 unique variables 
(e.g., diagnosis of weakness, wheelchair claim, home oxygen claim). The resulting predicted 
probabilities were categorized as 0–<10% (low probability of frailty), 10–<20% (low-
intermediate), 20–<50% (intermediate-high), and 50%+ (high). Finally, we constructed a 
variable for whether an individual underwent surgical resection or received chemotherapy or 
radiation in the 6-months following diagnosis. In addition, we constructed indicators for the 
use of specific chemotherapeutic agents in each month from diagnosis through month 11. 
Codes used to define cancer treatments from Medicare claims are listed in the 
Supplementary Materials.
Assessment of PIM Use
We identified PIMs according to the 2012 Beers criteria,(4) a medication screening tool 
developed to help healthcare providers optimize medication use in older adults. The Beers 
criteria, originally developed in 1991, have been regularly updated by the American 
Geriatrics Society. The 2012 Beers criteria include 34 drugs to avoid in older adults and 18 
drugs that should be avoided as they could exacerbate a coexisting disease (i.e., drug-disease 
interactions). Prevalence of any PIM dispensing was evaluated monthly, starting 6 months 
before and going through 23 months following the diagnosis month (month 0). The pre-
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cancer diagnosis period (months −6 to −1) was used to establish baseline PIM use patterns 
prior to a cancer diagnosis and to facilitate comparison with published prevalence estimates 
of PIM in the general older adult population. We selected the 23 months following the 
month of cancer diagnosis to evaluate patterns of PIM use during the initial treatment 
(month 0–11) and continuing (month 12–23) phases of cancer care,(18, 19) as the transitions 
in PIM prevalence related to cancer treatment were of particular interest. All analyses were 
anchored at the month of cancer diagnosis (month 0).
Of particular interest were PIMs related to the alleviation of cancer symptoms and 
treatment-related side effects (referred to as cancer-related PIMs). We specifically examined 
the broad Beers criteria categories of “Pain” and “Central Nervous System” to identify 
cancer-related PIMs for pain, anxiety/depression, and insomnia and then identified specific 
PIMs frequently used to manage nausea, diarrhea, and appetite in cancer patients. For 
presentation purposes, cancer-related PIM analyses were limited to specific PIMs that had a 
>1% prevalence in at least one month for at least one cancer site.
To be included in the denominator for a given month, individuals had to have: (1) at least 12 
months of continuous Medicare enrollment in Parts A and B prior to the given month of 
interest, (2) Medicare Part D (prescription drug) coverage during the month, and (3) at least 
one prescription medication dispensed (or days’ supply carried over) in a given month. 
Dispensing of a prescription medication was a requirement for an individual to contribute to 
the denominator, consistent with prior studies,(20–22) as an adult who is not receiving any 
prescription medications cannot be exposed to a PIM. Because eligibility was determined on 
a month-by-month basis, the number of individuals contributing to monthly prevalence 
measures changes over time.
PIMs were identified using Medicare Parts A, B, and D claims as described by Jiron et al.
(22) We first used the Anatomical Therapeutic Chemical (ATC) classification system to 
identify all medications and classes of medications listed as part of the 2012 Beers criteria 
and then developed a crosswalk of these medications to their specific National Drug Codes 
(NDCs). For PIMs due to drug-disease interactions, we used International Classification of 
Diseases, 9th Revision, Clinical Modification (ICD-9) codes to identify specific conditions in 
the 12-months prior to the given month of interest.
Assessment of drug interactions with chemotherapeutic agents
We identified potential drug-drug interactions involving chemotherapeutics through a review 
of the literature(13, 23–29) with confirmation by two clinical pharmacists with expertise in 
oncology and geriatrics. Our review was limited to potential interactions with 
chemotherapeutic agents used as initial treatment for stage I–III breast, II–III colon, or I–II 
lung cancer. We again used the ATC classification system to identify all medications 
included in our review and developed a crosswalk of these medications to their specific 
NDCs. A clinical pharmacist further classified each potential drug-chemotherapeutic 
interaction as minor (caution advised), moderate (monitor/modify therapy), or major 
(avoid/use alternative) using Micromedex® Online (Micromedex, Inc., Ann Arbor, MI, 
USA).
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The 12-month period prevalence of potential drug-chemotherapy interactions was evaluated 
on the specific chemotherapy agent-level during the initial treatment phase of care (month 
0–11). To be included in the denominator for the period prevalence analyses, individuals had 
to have: (1) continuous Medicare enrollment in Parts A, B, and D (and no managed care 
coverage) during the entire initial treatment phase and (2) at least one claim for the 
administration of a specific chemotherapeutic agent of interest in at least one month during 
this period. To be included in the numerator, patients had to have a prescription claim for a 
potential interacting drug and overlapping days’ supply with the administration of a specific 
chemotherapeutic agent of interest. For presentation purposes, we restricted our descriptive 
analyses to specific chemotherapies that had more than 100 patients in the denominator in an 
attempt to avoid imprecise estimates. All prevalence with a numerator of <11 were 
suppressed due to SEER-Medicare privacy rules. Specific chemotherapeutics included were 
5-fluorouracil (5-FU)/capecitabine (colon), cyclophosphamide (breast), doxorubicin (breast), 
methotrexate (breast), paclitaxel (breast, lung), carboplatin (lung), cisplatin (lung), etoposide 
(lung), and gemcitabine (lung). Tamoxifen (breast) was also included in analysis, but is 
considered endocrine therapy.
Statistical Analysis
We estimated the monthly point prevalence of any PIM among the three cancer cohorts from 
the 6 months before through the 23 months following the month of cancer diagnosis (month 
0). Given the specific interest in the influence of chemotherapy on the use of PIMs as 
supportive care agents, month-level analyses were stratified by chemotherapy receipt (yes 
versus no). The monthly prevalence of specific cancer-related PIMs was computed among 
the three cohorts. Finally, we estimated the 12-month period prevalence of potential drug-
chemotherapy interactions during the initial treatment phase, stratifying results by cancer 
site. All statistical analyses were performed in SAS version 9.4 (Cary, NC). This study was 
performed after approval by the University of North Carolina at Chapel Hill Institutional 
Review Board.
Results
Study population
After applying all study inclusion criteria, there were 19,318 stage I–III breast, 7,283 stage 
II–III colon, and 7,237 stage I–II lung cancer patients included in our baseline cohorts 
(Supplemental Table 1). Demographic and clinical characteristics of these patients are 
reported in Table 1. Median age at cancer diagnosis was similar across cohorts at 75 years 
for breast and lung cancer to 78 years for colon cancer. Variation in the burden of 
comorbidity at the time of cancer diagnosis was observed across the three cohorts, where 
lung cancer patients had the highest proportion of patients with a Charlson comorbidity 
score of 2 or more (lung: 36%, colon: 26%, and breast: 19%) and were dispensed the 
greatest number of prescription medications in the month prior to cancer diagnosis (% 
receiving 6+ medications, lung: 33%, colon: 27%, and breast: 25%). However, colon cancer 
patients had the highest probability of being frail (using a claims-based model), while breast 
cancer patients had the lowest probability. During the six months following cancer 
diagnosis, 98% of all colon cancer patients and 94% of breast cancer patients underwent 
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surgical resection, compared with only 46% of lung cancer patients. Chemotherapy was 
most common among colon cancer patients (34%), while radiation was frequent among 
breast cancer patients (44%).
Monthly prevalence of any PIM
The monthly prevalence of any PIM prior to cancer diagnosis was similar across all three 
cancer cohorts, hovering between 37–40% (Figure 1), similar to general population 
estimates among Medicare beneficiaries.(22) However, following cancer diagnosis, different 
patterns emerged. The prevalence of PIM among breast cancer patients consistently 
decreased over the period following diagnosis, whereas PIM prevalence sharply increased in 
the first few months following a colon or lung cancer diagnosis, and slowly decreased back 
to pre-diagnosis levels over the following 23 months. Decreases in PIM prevalence in the 
breast cancer cohort were attributable to decreased dispensing of estrogen following 
diagnosis (9% at six months prior to diagnosis to 0.5% one year after diagnosis).
Stratification by chemotherapy receipt
We further plotted the monthly prevalence of any PIM dispensing stratified by chemotherapy 
receipt (Figures 2a–c). Longitudinal patterns across cancer sites were consistent showing a 
sharp immediate increase in the monthly prevalence of both PIM dispensing among 
individuals who initiated chemotherapy within the first six months following cancer 
diagnosis. In contrast, the monthly prevalence of PIM remained relatively constant among 
those who do not initiate chemotherapy.
Most common cancer-related PIM drugs to be avoided
The monthly prevalence of cancer-related PIM use is presented in Figure 3a–c. Across all 
three cancer cohorts, the prevalence of amitriptyline use (a tricyclic antidepressant) was 
high, but remained relatively constant over the study period at 1.5–2.5%. The monthly 
prevalence of cyclobenzaprine (a muscle relaxant) was also steady, but lower across cohorts 
ranging from 0.5–1.5%. The lowest cancer-related PIM prevalence was for dicyclomine (an 
antispasmodic), which was also stable across the trajectory of care, with the exception of the 
colon cancer cohort, where a small spike in the month of diagnosis was observed.
For breast cancer, promethazine (an anti-emetic) was the most common cancer-related PIM, 
with a monthly prevalence that was elevated in the first nine months following cancer 
diagnosis (1%–3%), but returned to pre-diagnosis levels (<1%) thereafter. In the lung cancer 
cohort, the prevalence of promethazine and megestrol (a drug indicated to increase appetite) 
use increased after cancer diagnosis and remained elevated throughout the following year 
(promethazine: 1–3%; megestrol: 2–4%). The colon cancer cohort had the most cancer-
related PIM use, including a high prevalence of metoclopramide, a pro-motility drug used to 
speed transit after surgery, (3–4%) and promethazine (3%) use during the initial months 
following diagnosis. Increasing prevalence in belladonna alkaloid use, an antispasmodic, (2–
3%) and megestrol (1–3%) were largely sustained during the year following cancer 
diagnosis.
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Period prevalence of potential drug-chemotherapeutic interactions
The 12-month period prevalence for selected potential drug-chemotherapeutic interactions 
are presented in Table 2 along with a brief description of the potential interaction outcome 
(e.g., increased chemotherapy effect). Overall, the reported period prevalence of potential 
drug-chemotherapy interactions ranged from 1–31%. The most prevalent potential 
interactions in the colon cancer cohort were for 5-FU/capecitabine and hydrochlorothiazide 
(a diuretic used to manage blood pressure, 22%) and warfarin (a drug used to treat blood 
clots, 15%), both classified as moderate potential drug interactions. In the breast cancer 
cohort, the most prevalent potential interactions classified as major included 
cyclophosphamide and hydrochlorothiazide (31%) and methotrexate and non-steroidal anti-
inflammatory drugs (drugs used to inflammation, pain, and fever, 16%), while the most 
prevalent moderate interaction was for methotrexate in combination with proton-pump 
inhibitors (drugs used for suppression of gastric acid, 29%). Finally, in the lung cancer 
cohort, warfarin was considered a major interaction when used together with etoposide 
(14%) and gemcitabine (15%).
Discussion
Prior to cancer diagnosis, we observed that the vast majority of cancer patients used multiple 
prescription medications, many of which were considered to be potentially inappropriate 
according to the Beers criteria. However, following a cancer diagnosis, clear evidence of 
changes in patterns of medication use emerged, many as a direct result of cancer-related 
care. The prevalence of PIM dispensing increased following a diagnosis of colon and lung 
cancer, but decreased following a breast cancer diagnosis. When further stratified by 
chemotherapy receipt, changes in PIM prevalence were observed among those initiating 
chemotherapy in all cohorts. Further exploration of cancer-related PIM dispensing revealed 
that changes in PIM use were largely due to the addition of supportive care medications, in 
particular, anti-emetics and antispasmodic drugs. In addition, we observed a range of 
prevalence of potential drug-chemotherapy interactions across cohorts, with the most 
prevalent interactions involving hydrochlorothiazide, warfarin, and proton-pump inhibitors.
While a handful of studies have evaluated the prevalence of PIM use in older cancer patients 
at diagnosis or before initiating treatment,(30–34) only two prior studies have specifically 
used the 2012 Beers criteria to assess PIM prevalence. The first study by Maggiore et al(32) 
included 500 older adults with cancer initiating chemotherapy at seven academic medical 
centers in the United States. In this study, PIM prevalence, assessed via self-report and 
medical record verification, was 29%. This estimate is lower than that reported in our study, 
which may be due to the inclusion of: (1) only the Beers drugs to be avoided and not PIM 
drug-disease interactions and (2) individuals who were initiating chemotherapy. When 
restricted to older adults initiating chemotherapy, the PIM prevalence in our cohorts (prior to 
diagnosis) was lower (32–35%), likely because these populations are healthier and have a 
lower overall medication burden. The second study by Nightingale et al(33) was a conducted 
among 248 patients who underwent a routine comprehensive geriatric assessment at an 
academic medical center and had generally not received any cancer treatment or supportive 
care. PIM was assessed through a pharmacist-led medication review with the patient and/or 
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caregiver. The findings from this study are largely consistent with our results with a reported 
prevalence of PIM use (prior to cancer treatment) of 40%. Notably, neither of these studies 
evaluated patterns of PIM use over the trajectory of cancer care nor focused specifically on 
cancer-related PIM use. This information is important to clarify the unique medication-
related issues facing older adults newly diagnosed with cancer and their healthcare 
providers.
It is important to recognize that the classification of a prescription drug as a PIM or cancer-
related PIM only indicates that it might be inappropriate based on population-level data. 
There may be very good reasons for prescribing a medicine included on the Beers list, once 
the actual risks and benefits are considered within in the context of a particular individual 
and their cancer. Our findings indicate that changes in the prevalence of PIM dispensing over 
the course of cancer care are primarily driven by the use of supportive care medications 
among patients initiating chemotherapy. While some of these medications may not be 
considered inappropriate when administered in the oncology setting because of a lack of 
alternatives with fewer adverse effects (e.g., megestrol for appetite stimulation), others (e.g., 
metoclopramide or promethazine) have therapeutic alternatives with better benefit-risk 
profiles for older adult populations. If a PIM is used for treating an older adult with cancer, 
increased efforts to monitor and manage side effects may be warranted.
Only a handful of small studies have investigated the frequency of potential drug-drug 
interactions involving chemotherapies in cancer patients, and have found that drug 
interactions involving warfarin, quinolones, and antiepileptics are common,(23–28) 
consistent with our findings. Yet, no study evaluated the prevalence of these interactions 
among groups of older cancer patients truly at risk of an interaction (i.e., using a 
denominator of those patients receiving specific chemotherapies of interest). Thus, the 
estimates provided in this study fill an important gap clarifying the potential burden of these 
specific medication-related problems for cancer patients receiving chemotherapy. Still, 
caution is warranted when interpreting the potential drug-chemotherapy interaction analyses. 
Careful weighing of risks and benefits of specific medications in the context of a new cancer 
diagnosis and the expected benefits of cancer-directed treatment make these decisions 
particularly complex. In general, the severity of the potential drug-chemotherapy interaction 
may help to guide the level of concern and intervention or consultation with a pharmacy 
specialist.
We wholeheartedly concur with Nightingale and colleagues(33) that clinical pharmacists or 
pharmacologists can and should play a more prominent role in multidisciplinary teams 
caring for older adults with cancer. Pharmacy specialists are uniquely positioned to assess, 
plan, and optimize both oncology and non-oncology medications prior to beginning new 
cancer or supportive care treatments, as well as following the completion of cancer treatment 
by ensuring continuity and coordination of care with patients’ general practitioner and 
medical specialists. This broader review of medication quality and safety for older adults can 
ultimately lead to improved cancer- and non-cancer outcomes. We found that the burden of 
PIM use varied by cancer site and chemotherapy receipt. Given resource constraints in busy 
oncology clinics, focused medication reviews, led by a pharmacy specialist, might target 
populations with the highest likelihood of being exposed to a medication-related problem. In 
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this study, we found that changes in PIM prevalence were largely driven by the receipt of 
chemotherapy. Taken together with concerns about the potential for drug interactions with 
specific chemotherapeutic agents, this population might be a reasonable target for more in-
depth intervention via medication reviews.
The primary strengths of this study include the large, diverse study population of older 
breast, colon, and lung cancer patients treated in real world settings, expanding upon the 
generalizability of prior studies focused on patients treated in academic medical centers. In 
addition, our work provides an expanded view of PIM use by describing longitudinal 
patterns of PIM prevalence over the course of the cancer care continuum, highlighting 
subgroups and time points where PIM prevalence is increased. This analysis used 
prescription medication dispensing information to identify PIM, and thus captures a more 
complete assessment of prescription medications dispensed across various healthcare 
settings and providers, which is not subject to recall bias.
Our study is subject to some important limitations. Medicare claims data do not contain 
information on over-the-counter medications, herbal/supplements, or benzodiazepines (as 
they were not reimbursed by Medicare until 2013).(35) As such, the monthly PIM 
prevalence presented are likely underestimated, especially among patients initiating 
chemotherapy, where benzodiazepine prescribing is common.(36, 37) In addition, we did not 
attempt to identify all potential drug-chemotherapy interactions in our study cohort, but 
instead selected potential interactions for examination based on a literature review, 
indicating the most prevalent interactions. Finally, we did not evaluate specific outcomes of 
PIM dispensing or potential drug-chemotherapy interactions in older cancer patients (e.g., 
hospitalization, emergency department visits, mortality), however, we recognize this is an 
important area of future research.
Despite these limitations, this study has expanded our knowledge regarding potential 
medication-related problems among older adults newly diagnosed with breast, colon, and 
lung cancer over the course of cancer care. Our findings highlight the use of multiple 
supportive care medications and drug-interactions that may be considered potentially 
inappropriate among older cancer patients receiving chemotherapy. Physician assessment of 
medication risks and benefits and consideration of possible treatment alternatives seems 
reasonable, given the potentially adverse profile of these mediations in older adult 
populations. Given the unique and complex aspects of cancer-directed treatment and 
medication management among older adults newly diagnosed with cancer, inclusion of 
clinical pharmacists or pharmacologists on multidisciplinary teams caring for older cancer 
patients is warranted.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Monthly prevalence of any PIM by cancer site from 6 months before through 23 
months following the month of cancer diagnosis
The solid black line represents the stage I–III breast cancer cohort; the solid grey line 
represents the stage II–III colon cancer cohort; the dashed black line represents the stage I–II 
lung cancer cohort. The black vertical line denotes the month of cancer diagnosis.
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Figure 2. A–C. Monthly prevalence of PIM by cancer site from 6 months before through 23 
months following the month of cancer diagnosis, stratified by chemotherapy receipt (dashed line) 
versus no chemotherapy receipt (solid line)
Chemotherapy initiation was assessed during the 6 months following cancer diagnosis. The 
black vertical line denotes the month of cancer diagnosis. Monthly PIM prevalence is 
reported by cancer site for the breast (A), colon (B), and lung (C) cohorts.
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Figure 3. A–C. Monthly prevalence of cancer-related PIM from 6 months before through 23 
months following the month of cancer diagnosis by cancer site
All medications included in the analysis had a prevalence of >1% in at least one month for at 
least one cancer site. The black vertical line denotes the month of cancer diagnosis. Monthly 
cancer-related PIM prevalence is reported by cancer site for the breast (A), colon (B), and 
lung (C) cohorts.
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